[整理版]早期胃癌化疗计谋.pptVIP

晚期胃癌化疗策略;晚期胃癌治疗现状;胃癌化疗;晚期胃癌化疗临床问题; 药物、方案的选择;Randomized Phase III Study : 1990-2000;欧洲实践标准;亚洲实践标准;晚期胃癌化疗现状;新世纪初的选择…;Docetaxel, 5-FU and Cisplatin: V 325 Phase III;胃癌III期临床----TAX 325随访结果;TAX325: increased febrile neutropenia with TCF;TAX 325 研究结果;CPT-11 for AGC——Ⅱ期多中心临床研究（2003 ASCO）FFCD 9803 法国;CPT-11联合5-FU治疗AGC----III期临床试验（2005 ASCO）;新世纪初的选择：问题！…;新的探索和循证医学证据;REAL 2randomised multicentre phase III study comparing capecitabine with 5-FU and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer;REAL-2: randomized, phase III trial in gastric and GEJ cancer;REAL 2: 研究目标;REAL 2 interim analysis: good response with oxali- vs. cisplatin;;Updated results for four regimens;;REAL 2: conclusions;Oxaliplatin联合EPI、5-FU/CF治疗晚期胃癌的临床多中心研究—— china;first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP);Superior Performance with FLO vs. FLP;奥沙利铂＋5FU作为一线治疗;Oxaliplatin/CF/5-FU vs paclitaxel/CF/5-FU in pats with advanced gastric cancerA phase II clinical trial ;Phase II multicenter trial of docetaxel + oxaliplatin in stage IV gastroesophageal and/or stomach cancer;Results: efficacy;;ML17032 : CAPE vs 5-FU trial design;Superior response rate with XP vs. FP;ML17032 : XP vs FPprogression-free survival HR 0.81 ;Similar all-grades hematologic adverse events: XP vs. FP;A Phase II Trial of Capecitabine and DDP in AGC－－China;Summary of Combination Chemotherapy with CAPE in AGC;CAPE vs 5-FU in doublet regimens for AGC;新的探索和循证医学证据;伊立替康联合5-FU/LV、CDDP治疗胃癌;伊立替康联合奥沙利铂治疗胃癌; irinotecan plus capecitabine in patients with AGC ;S-1 80 mgm2 d1 - 14 q28d CPT-11 70-100 mgm2 d1 , 8 q 4 weeks, phase I : MTD : CPT-11 90 mg/m2 RD 80 mg/m2. phase II: 42 pats The median treatment course was 5 (range: 1–13). RR 62% (95% confidence interval: 47.2–76.6%), The median survival time was 444 days. grade 3–4haematological 19% ; nonhaematological toxicities 10%,;N=45/48 irinotecan 150 mg/